CX 2021 Programme

- Tuesday, 26th April
Venue:   Kensington 1
CX effect of COVID 19 challenges upon vascular management now and future 08:00-09:00
Co-detect outcomes: Imperial College and Northwick Park Hospital
Speaker:   Kamran Modaresi, Harrow, United Kingdom
Co-detect outcomes: St George's Hospital
Speaker:   TBA
Co-detect outcomes: Helsinki University Hospital
Speaker:   Maarit Venermo, Helsinki, Finland
International Venous pathways
Speaker:   Sergio Gianesini, Ferrara, Italy
Covid 19 associated thromboses
Covid 19 Acute Limb Ischaemia
Speaker:   TBA
COVID 19 Challenges to skills learning and training of vascular specialists 09:00-10:00
Covid 19 and training numbers
Speaker:   Ginny Bowbrick, Gillingham, United Kingdom
Covid 19 and Vascular Surgical training in Great Britain and Ireland - The Rouleaux club view
Speaker:   James Rammell, Newcastle upon Tyne, United Kingdom
Covid 19 as seen by the European Society For Vascular Surgeons in Training (EVST)
Speaker:   Stefano Ancetti, Bologna, Italy
Covid 19 Challenges to the final Board Qualification in Surgery
Speaker:   TBA
Covid 19 challenges on patients in North America: The SVS view
Speaker:   TBA
Networking break - Coffee 10:00-10:30
Peripheral Arterial Challenges 10:30-11:30
Timely interventions by specialists and guideline-based treatment to reduce amputation rates
Speaker:   TBA
Directional atherectomy (DA) plus DCB to treat long, calcified femoropopliteal artery lesions: The REALITY study
Speaker:   Thomas Zeller, Bad Krozingen, Germany
Initial experience with a new angioplasty balloon to maximize dilatation efficiency - the Boston Scientific Athletis balloon
Speaker:   Andrew Holden, Auckland, New Zealand
A new hybrid approach to limit blood loss while treating large popliteal artery aneurysms
Speaker:   Enrico Ascher, New York, United States
Safety update on peripheral paclitaxel coated stents
Speaker:   Peter Schneider, San Francisco, United States
Peripheral Arterial Challenges Continued 11:30-12:30
Calcium Definitions in Endovascular Clinical Trials: Is the Struggle Real?
Speaker:   Ralf Langhoff, Berlin, Germany
Podium 1st: The place of neuromascular electrical stimulation for intermittent claudication, randomised control trial data NeSIC trial
Speaker:   Alun Davies, London, United Kingdom
Popliteal artery occlusive disease - NICE Guidelines
Speaker:   Trevor Cleveland, Sheffield, United Kingdom
Risk of major amputation in patients with intermittent claudication undergoing early revascularization (higher mortality risk in Australia from overly-aggressive revascularisation in claudicants)
Speaker:   Jonathan Golledge, Townsville, Australia
Zilverpass - Final 36-month update including financial update
Speaker:   Marc Bosiers, Dendermonde, Belgium
Achieving optimum outcomes using self expandable covered stents in the superficial femoral artery - Insights from the various Japanese trials
Speaker:   Osamu Iida, Amagasaki, Japan
Networking break - Lunch 13:00-13:30
Proximal Peripheral Arterial Challenges 13:30-14:30
Safety update on peripheral paclitaxel coated stents
Speaker:   Eric Secemsky, Boston, United States
Vascular response of a polymer-free, paclitaxel-coated stent (zilver ptx) versus a polymer-coated, paclitaxel-eluting stent (eluvia) in healthy swine femoropopliteal arteries
Speaker:   TBA
5-Year Results from the IN.PACT Global Study Pre-specified Cohorts: In-Stent Restenosis, Chronic Total Occlusions and Long Lesions
Speaker:   Gunnar Tepe, Rosenheim, Germany
Clinical outomes with drug-coated balloon alone vs drug-coated balloon plus provisional stenting: An analysis from the IN.PACT global study 5-year data
Speaker:   Gary Ansel, Columbus, United States
FDA regulatory update on paclitaxel
Speaker via Zoom:   Misti Malone, Silver Spring, United States
MHRA regulatory update on paclitaxel
Speaker:   TBA